Skip to main content
Salarius Pharmaceuticals, Inc. logo

Salarius Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · SLRX ISIN · US79400X4043 LEI · 549300CLUMLZXIHU7X22 US Professional, scientific and technical activities
Open in API
Filings indexed 700 across all filing types
Latest filing 2018-10-26 Major Shareholding Noti…
Country US United States of America
Listing US SLRX

About Salarius Pharmaceuticals, Inc.

https://salariuspharma.com/

Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing therapies for cancer patients with high unmet medical needs. The company's core technology focuses on correcting the dysregulated gene expression of cancer cells, a key driver of disease development. Its pipeline includes two classes of drugs: targeted protein inhibitors (TPIs) and targeted protein degraders (TPDs). The lead TPI candidate, seclidemstat (SP-2577), is in Phase 1/2 clinical trials, while the lead TPD candidate, SP-3164, is in IND-enabling studies. These therapeutic candidates are being developed to treat solid and hematologic cancers, including leukemias and lymphomas.

Recent filings

Filing Released Lang Actions
SC 13D
Major Shareholding Notification
2018-10-26 English
SC 13D/A
Major Shareholding Notification
2018-10-26 English
4
Director's Dealing
2018-10-18 English
4
Director's Dealing
2018-10-18 English
8-K
Delisting Announcement Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated September 27, 2018, by Flex Pharma, Inc. The content focuses on a notice received from Nasdaq regarding the company's failure to meet continued listing requirements due to market value and bid price thresholds. It details the compliance periods and potential delisting consequences but does not contain financial statements or detailed financial data. The primary subject is the notice of potential delisting and related compliance information. According to the filing definitions, this matches the category of a Delisting Announcement (DLST). The document length is 4691 characters, which is sufficient to contain substantive information rather than a mere announcement of a report. Therefore, the classification is DLST with high confidence.
2018-10-01 English
SC 13G/A
Major Shareholding Notification
2018-09-10 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.